Who we are

RusnanoMedInvest (RMI, subsidiary of RUSNANO) is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology

RMI was created in March 2012. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government. 

The key strategic objective RusnanoMedInvest is to create a Russian-domiciled locus of  world-class expertise in venture capital fundraising, deal origination and execution in  Life Sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting edge technologies.

RusnanoMedInvest  is now evaluating a wide range of life sciences and pharmaceuticals investment opportunities with a view to investing in approximately 20 promising technologies and localizing these technologies in Russia.

Ultimately the goal of these investments and associated localization strategies is to significantly reduce the introduction lead time of new and innovative medicines and medical devices in Russia targeted at delivering significant therapeutic benefits and efficiencies in disease areas that are classified as socially significant complex, poorly treated and widely prevalent diseases in Russia  in cases where no domestically sourced, effective treatment methods are available today.

All Portfolio


  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.